Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer

Wang, De-Shen, Liu, Ze-Xian, Lu, Yun-Xin, Bao, Hua, Wu, Xue, Zeng, Zhao-Lei, Liu, Zekun, Zhao, Qi, He, Cai-Yun, Lu, Jia-Huan, Wang, Zhi-Qiang, Qiu, Miao-Zhen, Wang, Feng, Wang, Feng-Hua, Li, Yu-Hong, Wang, Xiao-Nan, Xie, Dan, Jia, Wei-Hua, Shao, Yang W, Xu, Rui-Hua·2019·Gut

Abstract

Objective: To monitor trastuzumab resistance and determine the underlying mechanisms for the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric cancer (mGC). Design: Targeted sequencing of 416 clinically relevant genes was performed in 78 paired plasma and tissue biopsy samples to determine plasma-tissue concordance. Then, we performed longitudinal analyses of 97 serial plasma samples collected from 24 patients who were HER2+ to track the resistance during trastuzumab treatment and validated the identified candidate resistance genes. Results: The results from targeted sequencing-based detection of somatic copy number alterations (SCNA) of HER2 gene were highly consistent with fluorescence in situ hybridisation data, and the detected HER2 SCNA was better than plasma carcinoembryonic antigen levels at predicting tumour shrinkage and progression. Furthermore, most patients with innate trastuzumab resistance presented high HER2 SCNA during progression compared with baseline, while HER2 SCNA decreased in patients with acquired resistance. PIK3CA mutations were significantly enriched in patients with innate resistance, and ERBB2/4 genes were the most mutated genes, accounting for trastuzumab resistance in six (35.3%) and five (29.4%) patients in baseline and progression plasma, respectively. Patients with PIK3CA/R1/C3 or ERBB2/4 mutations in the baseline plasma had significantly worse progression-free survival. Additionally, mutations in NF1 contributed to trastuzumab resistance, which was further confirmed through in vitro and in vivo studies, while combined HER2 and MEK/ERK blockade overcame trastuzumab resistance. Conclusion: Longitudinal circulating tumour DNA sequencing provides novel insights into gene alterations underlying trastuzumab resistance in HER2+mGC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-316522

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 195

Metadata

Authors
Wang, D.-S., Liu, Z.-X., Lu, Y.-X., Bao, H., Wu, X., Zeng, Z.-L., Liu, Z., Zhao, Q., He, C.-Y., Lu, J.-H., Wang, Z.-Q., Qiu, M.-Z., Wang, F., Wang, F.-H., Li, Y.-H., Wang, X.-N., Xie, D., Jia, W.-H., Shao, Y. W., & Xu, R.-H.
Venue
Gut
Publisher
BMJ
Published
2018-09-29
Volume
68
Issue
7
Pages
1152-1161
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2893194336
Cited by
195
References
8
FWCI
5.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. https://app.cochat.ai/papers/10.1136/gutjnl-2018-316522
The paper
Wang, D.-S., Liu, Z.-X., Lu, Y.-X., Bao, H., Wu, X., Zeng, Z.-L., Liu, Z., Zhao, Q., He, C.-Y., Lu, J.-H., Wang, Z.-Q., Qiu, M.-Z., Wang, F., Wang, F.-H., Li, Y.-H., Wang, X.-N., Xie, D., Jia, W.-H., Shao, Y. W., & Xu, R.-H. (2019). Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. https://doi.org/10.1136/gutjnl-2018-316522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.